Brief: Oragenics Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients
21/08/2024 14:07
Aug 21 (Reuters) - Oragenics Inc OGEN.A :
* ORAGENICS INC. COMPLETES SPRAY DRY DRUG MANUFACTURING AND
INTRANASAL DEVICE FILLING IN ANTICIPATION OF PHASE IIA CLINICAL
TRIAL IN CONCUSSED PATIENTS
Source text for Eikon: ID:nGNX3Rqj2V
Further company coverage: OGEN.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Oragenics
See all newsBrief: Oragenics Reports Continued Clinical Progress, Provides Regulatory And NYSE American Listing Update
Brief: Oragenics Signs Letter Of Intent To License Cardiodialysis™ Technology From Sigyn Therapeutics To Target Tbi-Induced Systemic Inflammation
Brief: Oragenics Inc - Signs Letter Of Intent To License Cardiodialysis From Sigyn Therapeutics - SEC Filing
Brief: Oragenics Activates Second Site In Phase Iia Clinical Trial Of Onp-002 For Concussion And Mild Traumatic Brain Injury.
Brief: Oragenics Enters Settlement Agreement With Ladenburg Thalmann - Sec Filing